Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine

Cell Biochemistry and Function

Volumn 29, Issue 8, 2011, Pages 651-659

  Ari, Ferda ^a   Napieralski, Rudolf ^b   Ulukaya, Engin ^a   Dere, Egemen ^a   Colling, Christoph ^b   Honert, Katja ^b   Krüger, Achim ^b   Kiechle, Marion ^b   Schmitt, Manfred ^b  

^a ULUDAG UNIVERSITY   (Turkey)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Apoptosis; Breast cancer; Decitabine; DNA methylation; M30 antigen; PAI 1; UPA

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 5 AZA 2' DEOXYCYTIDINE; ADENOSINE TRIPHOSPHATE; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CELL ACTIVITY; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA METHYLATION; DRUG EFFECT; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; SINGLE DRUG DOSE;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 83055194490     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1801     Document Type: Article

References (36)

1. Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC. Early breast cancer. Lancet 2009; 373: 1463-1479.
2. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
3. Cavallaro U, Christofori G. Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough. Biochim Biophys Acta 2001; 1552: 39-45.
4. Schmitt M, Harbeck N, Thomssen C, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997; 78: 285-296.
5. Schmitt M, Jänicke F, Moniwa N, Chucholowski N, Pache L, Graeff H. Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe Seyler 1992; 373: 611-622.
6. Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005; 93: 631-640.
7. Harbeck N, Kates RE, Gauger K, et al. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost 2004; 91: 450-456.
8. Witzel ID, Milde-Langosch K, Wirtz RM, et al. Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome. J Cancer Res Clin Oncol 2010; 136: 1709-1718.
9. Esteller M. Epigenetics in cancer. New Engl J Med 2008; 358: 1148-1159.
10. Cortez CC, Jones PA. Chromatin, cancer and drug therapies. Mutation Res 2008; 647: 44-51.
11. Ateeq B, Unterberger A, Szyf M, Rabbani SA. Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia 2008; 10: 266-278.
12. Guo Y, Pakneshan P, Gladu J, Slack A, Szyf M, Rabbani SA. Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion. J Biol Chem 2002; 277: 41571-41579.
13. Gao S, Skeldal S, Krogdahl A, Sorensen JA, Andreasen PA. CpG methylation of the PAI-1 gene 5'-flanking region is inversely correlated with PAI-1 mRNA levels in human cell lines. Thromb Haemost 2005; 94: 651-660.
14. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55: 5276-5282.
15. Kurbacher CM, Cree IA, Bruckner HW, Brenne U, Kurbacher JA, Muller K, et al. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anti-cancer Drugs 1998; 9: 51-57.
16. Ulukaya E, Ozdikicioglu F, Oral AY, Demirci M. The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested. Toxicol In Vitro 2008; 22: 232-239.
17. Napieralski R, Ott K, Kremer M, Becker K, Boulesteix AL, Lordick F, et al. Methylation of tumor-related genes in neoadjuvant-treated gastric cancer: relation to therapy response and clinicopathologic and molecular features. Clin Cancer Res 2007; 13: 5095-5102.
18. Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, et al. Analysis of repetitive element DNA methylation by MethyLight. Nucl Acids Res 2005; 33: 6823-6836.
19. Pakneshan P, Szyf M, Farias-Eisner R, Rabbani SA. Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J Biol Chem 2004; 279: 31735-31744.
20. Pakneshan P, Tetu B, Rabbani SA. Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma. Clin Cancer Res 2004; 10: 3035-3041.
21. Lo PK, Sukumar S. Epigenomics and breast cancer. Pharmacogenomics 2008; 9: 1879-1902.
22. Lopez J, Percharde M, Coley HM, Webb A, Crook T. The context and potential of epigenetics in oncology. British J Cancer 2009; 100: 571-577.
23. Xu J, Zhou JY, Tainsky MA, Wu GS. Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2'-deoxycytidine sensitizes human breast cancer cells to adriamycin. Cancer Res 2007; 67: 1203-1211.
24. Mirza S, Sharma G, Pandya P, Ralhan R. Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents. Moll Cell Biochem 2010; 342: 101-109.
25. Nguyen DX. Tracing the origins of metastasis. J Pathol 2011; 223: 195-204.
26. Suh I, Weng J, Fernandez-Ranvier G, et al. Antineoplastic effects of decitabine, an inhibitor of DNA promoter methylation, in adrenocortical carcinoma cells. Arch Surg 2010; 145: 226-232.
27. Yi XM, Gong J, Dong J, et al. Inhibitory effect of 5-aza-2'-deoxycytidine combined with docetaxel on prostate cancer PC3 cells in vitro. Zhonghua Nan Ke Xue 2011; 17: 247-253.
28. Chen MY, Liao WS, Lu Z, et al. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer 2011; doi: 10.1002/cncr.26073. [Epub ahead of print]
29. Chai Y, Lee HJ, Shaik AA, et al. Penta- O-galloyl-β-D-glucose induces G1 arrest and DNA replicative S-phase arrest independently of P21 cyclin-dependent kinase inhibitor 1A, P27 cyclin-dependent kinase inhibitor 1B and P53 in human breast cancer cells and is orally active against triple-negative xenograft growth. Breast Cancer Res 2010; 12: R67.
30. Kannappan R, Ravindran J, Prasad S, et al. Gamma-tocotrienol promotes TRAIL-induced apoptosis through reactive oxygen species/extracellular signal-regulated kinase/p53-mediated upregulation of death receptors. Mol Cancer Ther 2010; 9: 2196-2207.
31. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
32. Annecke K, Schmitt M, Euler U, Zerm M, Paepke D, Paepke S, et al. uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem 2008; 45: 31-45.
33. Duffy MJ. Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers. Biochem Soc Trans 2002; 30: 207-210.
34. Harbeck N, Schmitt M, Paepke S, Allgayer H, Kates RE. Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms. Crit Rev Clin Lab Sci 2007; 44: 179-201.
35. Schmitt M, Mengele K, Napieralski R, et al. Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 2010; 10: 1051-1067.
36. Pakneshan P, Szyf M, Rabbani SA. Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: prognostic and therapeutic implications. Curr Cancer Drug Targets 2005; 5: 471-488.